Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study

Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using th...

Full description

Saved in:
Bibliographic Details
Published inPsychopharmacologia Vol. 191; no. 2; pp. 333 - 339
Main Authors Klein, Nikolas, Sacher, Julia, Geiss-Granadia, Thomas, Mossaheb, Nilufar, Attarbaschi, Trawat, Lanzenberger, Rupert, Spindelegger, Christoph, Holik, Alexander, Asenbaum, Susanne, Dudczak, Robert, Tauscher, Johannes, Kasper, Siegfried
Format Journal Article
LanguageEnglish
Published Berlin Springer 01.04.2007
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [(123)I]ADAM and single photon emission computed tomography (SPECT). Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [(123)I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake. At 6 h after the last dose, mean SERT occupancies were 81.5 +/- 5.4% (mean+/-SD) for escitalopram and 64.0 +/- 12.7% for citalopram (p < 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 +/- 12.1% for escitalopram and 49.0 +/- 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain. The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT.
AbstractList Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [(123)I]ADAM and single photon emission computed tomography (SPECT). Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [(123)I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake. At 6 h after the last dose, mean SERT occupancies were 81.5 +/- 5.4% (mean+/-SD) for escitalopram and 64.0 +/- 12.7% for citalopram (p < 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 +/- 12.1% for escitalopram and 49.0 +/- 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain. The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT.
Objectives: Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [ super(123)I]ADAM and single photon emission computed tomography (SPECT). Methods: Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [ super(123)I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake. Results: At 6 h after the last dose, mean SERT occupancies were 81.5 plus or minus 5.4% (mean plus or minus SD) for escitalopram and 64.0 plus or minus 12.7% for citalopram (p < 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 plus or minus 12.1% for escitalopram and 49.0 plus or minus 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain. Conclusion: The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT.
Objectives: Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [123I]ADAM and single photon emission computed tomography (SPECT). Methods: Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [123I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake. Results: At 6 h after the last dose, mean SERT occupancies were 81.5 +/- 5.4% (mean±SD) for escitalopram and 64.0 +/- 12.7% for citalopram (p 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 +/- 12.1% for escitalopram and 49.0 +/- 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain. Conclusion: The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT. [PUBLICATION ABSTRACT]
Author Asenbaum, Susanne
Spindelegger, Christoph
Holik, Alexander
Kasper, Siegfried
Tauscher, Johannes
Klein, Nikolas
Attarbaschi, Trawat
Lanzenberger, Rupert
Sacher, Julia
Geiss-Granadia, Thomas
Mossaheb, Nilufar
Dudczak, Robert
Author_xml – sequence: 1
  givenname: Nikolas
  surname: Klein
  fullname: Klein, Nikolas
– sequence: 2
  givenname: Julia
  surname: Sacher
  fullname: Sacher, Julia
– sequence: 3
  givenname: Thomas
  surname: Geiss-Granadia
  fullname: Geiss-Granadia, Thomas
– sequence: 4
  givenname: Nilufar
  surname: Mossaheb
  fullname: Mossaheb, Nilufar
– sequence: 5
  givenname: Trawat
  surname: Attarbaschi
  fullname: Attarbaschi, Trawat
– sequence: 6
  givenname: Rupert
  surname: Lanzenberger
  fullname: Lanzenberger, Rupert
– sequence: 7
  givenname: Christoph
  surname: Spindelegger
  fullname: Spindelegger, Christoph
– sequence: 8
  givenname: Alexander
  surname: Holik
  fullname: Holik, Alexander
– sequence: 9
  givenname: Susanne
  surname: Asenbaum
  fullname: Asenbaum, Susanne
– sequence: 10
  givenname: Robert
  surname: Dudczak
  fullname: Dudczak, Robert
– sequence: 11
  givenname: Johannes
  surname: Tauscher
  fullname: Tauscher, Johannes
– sequence: 12
  givenname: Siegfried
  surname: Kasper
  fullname: Kasper, Siegfried
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18603179$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/17235610$$D View this record in MEDLINE/PubMed
BookMark eNp9kU9rFDEYh4NU7Hb1A3iRINjb6JtkJjPrbVlbW6goWE8iIZs_mjKTjEnmMJ_BL22GXVnowVxe8vL8Qvg9F-jMB28QekngLQFo3yUASlgFwCvgnFfzE7QiNaMVhZaeoRUAYxUjTXeOLlJ6gHLqrn6GzklLWcMJrNCfG_fzl4k4mRhy8M7jHKVPY4i5bINS0yi9mrG0y32Y-uzG3mAdksFSD867VALZBY-DxSYpl2UfxigHrMIwymg0zgGf1u-x9Pg7oez2x_bD9hP--uVqd49TnvT8HD21sk_mxXGu0bfrq_vdTXX3-ePtbntXqZrSXPEajG67fUekBasbut9Y1VLNNdtsOJONrFtugHXAbKuV1ZawjpXJGmasJmyNLg_vjjH8nkzKYnBJmb6X3oQpCVJeqZtS5Bq9fgQ-hCn68jdBSbfhnPEFenWEpv1gtBijG2Scxb-OC_DmCMikZG9Lv8qlE9dxYKTdFI4cOBVDStHYEwJi8S0OvkXxLRbfYi6Z9lFmaXrRUay4_j_JvweYsE8
CODEN PSYPAG
CitedBy_id crossref_primary_10_1038_bjp_2008_243
crossref_primary_10_1002_med_20245
crossref_primary_10_1007_s00213_016_4364_0
crossref_primary_10_1177_0269881115620462
crossref_primary_10_2174_1871527321666220301122807
crossref_primary_10_1016_j_neuroimage_2014_12_044
crossref_primary_10_1016_j_jpsychires_2008_11_004
crossref_primary_10_3389_fpsyt_2022_972141
crossref_primary_10_1590_S0100_879X2010005000007
crossref_primary_10_1016_j_nucmedbio_2010_02_010
crossref_primary_10_1097_YIC_0b013e32832a8ec8
crossref_primary_10_1586_14737175_8_4_537
crossref_primary_10_1097_FTD_0000000000001142
crossref_primary_10_1016_j_nucmedbio_2016_04_003
crossref_primary_10_1038_npp_2008_148
crossref_primary_10_2165_11204760_000000000_00000
crossref_primary_10_3390_biom10060880
crossref_primary_10_1016_j_euroneuro_2008_12_003
crossref_primary_10_1111_jsm_12980
crossref_primary_10_1017_S1461145709990149
crossref_primary_10_1016_j_neuroimage_2009_10_013
crossref_primary_10_1586_erd_09_64
crossref_primary_10_1038_s41380_021_01285_w
crossref_primary_10_1177_0269881110374782
crossref_primary_10_1007_s00213_009_1649_6
crossref_primary_10_1016_S2215_0366_15_00232_1
crossref_primary_10_1177_0269881109349835
crossref_primary_10_1002_hbm_25760
crossref_primary_10_1097_FTD_0000000000000824
crossref_primary_10_1007_s00213_014_3595_1
crossref_primary_10_1016_j_pscychresns_2008_12_006
crossref_primary_10_1016_j_xphs_2017_05_007
crossref_primary_10_1016_j_pscychresns_2016_03_006
crossref_primary_10_1136_bmjopen_2011_000544
crossref_primary_10_1080_15622975_2021_1878427
crossref_primary_10_1016_j_euroneuro_2016_09_001
crossref_primary_10_2967_jnumed_107_046102
crossref_primary_10_1016_j_neuroimage_2012_07_023
crossref_primary_10_1097_JCP_0b013e3182228619
crossref_primary_10_1517_17425255_2014_863873
crossref_primary_10_1523_JNEUROSCI_2409_10_2010
crossref_primary_10_1016_j_euroneuro_2009_01_010
crossref_primary_10_1586_14737175_8_12_1853
crossref_primary_10_1007_s00259_010_1424_2
crossref_primary_10_1186_s13195_017_0298_y
crossref_primary_10_3109_15563650903585937
crossref_primary_10_1016_j_neuroimage_2013_08_036
Cites_doi 10.1007/s00213-006-0486-0
10.2165/00003495-200565160-00013
10.1097/00004850-200505000-00002
10.1016/S0028-3908(03)00138-2
10.1038/sj.mp.4001009
10.1016/j.nucmedbio.2004.10.001
10.1016/S0969-8051(00)00084-6
10.1016/S0149-2918(03)80076-0
10.1176/appi.ajp.158.11.1843
10.1097/00007691-199906000-00001
10.1185/030079905X65484
10.1111/j.1600-0447.1987.tb10566.x
10.1097/01.jcp.0000203201.34323.d3
10.1080/13651500410005504
10.1176/appi.ajp.161.5.826
10.2165/00023210-199708050-00009
10.1007/s00702-005-0429-7
10.1177/0091270005280860
10.1016/0006-8993(89)90511-8
10.3109/15622970209150599
10.1177/00912700122010041
ContentType Journal Article
Copyright 2007 INIST-CNRS
Springer-Verlag 2007
Copyright_xml – notice: 2007 INIST-CNRS
– notice: Springer-Verlag 2007
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
88G
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
K9.
KB0
M0S
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
DOI 10.1007/s00213-006-0666-y
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Animal Behavior Abstracts
Chemoreception Abstracts
Nursing & Allied Health Database
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
ProQuest Health & Medical Collection
Medical Database
Psychology Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
Chemoreception Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
Animal Behavior Abstracts
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
DatabaseTitleList MEDLINE
Neurosciences Abstracts
ProQuest One Psychology
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central Database Suite (ProQuest)
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
Psychology
EISSN 1432-2072
EndPage 339
ExternalDocumentID 1228010111
17235610
18603179
10_1007_s00213_006_0666_y
Genre Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID 40D
40E
95.
95~
AAYXX
ABMNI
AGWIL
ALMA_UNASSIGNED_HOLDINGS
CITATION
RHV
SBY
SOJ
~EX
-4W
-BR
.55
3SX
IQODW
KOW
N2Q
R9-
X7M
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QG
7QR
7RV
7TK
7X7
7XB
88E
8AO
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GNUQQ
K9.
M1P
M2M
NAPCQ
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
ID FETCH-LOGICAL-c422t-640ed78b81af0fd52b9fc72d6d39963a5a476e03803f7dcfdf1383cfd353efd13
IEDL.DBID 7X7
ISSN 0033-3158
IngestDate Fri Jul 11 03:40:52 EDT 2025
Thu Aug 14 10:37:03 EDT 2025
Sat Sep 28 07:57:53 EDT 2024
Tue Sep 20 22:57:10 EDT 2022
Tue Jul 01 04:16:30 EDT 2025
Thu Apr 24 23:02:38 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords [123I]ADAM
Serotonin
Escitalopram
Psychotropic
Reuptake inhibitor
Photon
SPECT
Selective serotonin reuptake inhibitor
Citalopram
Multiple dose
5-HTT
SERT
Serotonin transporter
Occupancy
Neurotransmitter
Antidepressant agent
Emission tomography
Language English
License http://www.springer.com/tdm
CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c422t-640ed78b81af0fd52b9fc72d6d39963a5a476e03803f7dcfdf1383cfd353efd13
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
PMID 17235610
PQID 218966364
PQPubID 47309
PageCount 7
ParticipantIDs proquest_miscellaneous_19634514
proquest_journals_218966364
pubmed_primary_17235610
pascalfrancis_primary_18603179
crossref_primary_10_1007_s00213_006_0666_y
crossref_citationtrail_10_1007_s00213_006_0666_y
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2007-04-01
PublicationDateYYYYMMDD 2007-04-01
PublicationDate_xml – month: 04
  year: 2007
  text: 2007-04-01
  day: 01
PublicationDecade 2000
PublicationPlace Berlin
PublicationPlace_xml – name: Berlin
– name: Germany
– name: Heidelberg
PublicationTitle Psychopharmacologia
PublicationTitleAlternate Psychopharmacology (Berl)
PublicationYear 2007
Publisher Springer
Springer Nature B.V
Publisher_xml – name: Springer
– name: Springer Nature B.V
References A Takano (666_CR22) 2006; 26
S Kasper (666_CR7) 2004; 8
O Lingjaerde (666_CR12) 1987; 334
JH Meyer (666_CR14) 2004; 161
A Mork (666_CR16) 2003; 45
SJ Kish (666_CR9) 2005; 32
N Herold (666_CR6) 2006; 113
666_CR20
JH Meyer (666_CR13) 2001; 158
S Noble (666_CR18) 1997; 8
MM Gutierrez (666_CR5) 2003; 25
N Moore (666_CR15) 2005; 20
M Bauer (666_CR2) 2002; 3
P Voirol (666_CR24) 1999; 21
N Klein (666_CR10) 2006; 3
L Colonna (666_CR4) 2005; 21
P Baumann (666_CR3) 1995; 6
D Murdoch (666_CR17) 2005; 65
S Oya (666_CR19) 2000; 27
I Backstrom (666_CR1) 1989; 486
C Sanchez (666_CR25) 2004; 174
B Sogaard (666_CR21) 2005; 45
J Tauscher (666_CR23) 2002; 7
F Larsen (666_CR11) 2001; 41
11920159 - Mol Psychiatry. 2002;7(3):317-21
16238906 - Curr Med Res Opin. 2005 Oct;21(10):1659-68
2525060 - Brain Res. 1989 May 8;486(2):261-8
12842122 - Neuropharmacology. 2003 Aug;45(2):167-73
11269575 - J Clin Pharmacol. 2001 Mar;41(3):340-6
16291715 - J Clin Pharmacol. 2005 Dec;45(12):1400-6
16266205 - Drugs. 2005;65(16):2379-404
15121647 - Am J Psychiatry. 2004 May;161(5):826-35
15812262 - Int Clin Psychopharmacol. 2005 May;20(3):131-7
11691690 - Am J Psychiatry. 2001 Nov;158(11):1843-9
16633150 - J Clin Psychopharmacol. 2006 Apr;26(2):188-91
12809966 - Clin Ther. 2003 Apr;25(4):1200-10
15721757 - Nucl Med Biol. 2005 Feb;32(2):123-8
15160261 - Psychopharmacology (Berl). 2004 Jul;174(2):163-76
10832081 - Nucl Med Biol. 2000 Apr;27(3):249-54
16465456 - J Neural Transm (Vienna). 2006 May;113(5):659-70
12479086 - World J Biol Psychiatry. 2002 Jan;3(1):5-43
16955282 - Psychopharmacology (Berl). 2006 Oct;188(3):263-72
24930684 - Int J Psychiatry Clin Pract. 2004;8 Suppl 1:15-8
10365634 - Ther Drug Monit. 1999 Jun;21(3):263-6
2887090 - Acta Psychiatr Scand Suppl. 1987;334:1-100
References_xml – volume: 3
  start-page: 263
  year: 2006
  ident: 666_CR10
  publication-title: Psychopharmacology
  doi: 10.1007/s00213-006-0486-0
– volume: 65
  start-page: 2379
  year: 2005
  ident: 666_CR17
  publication-title: Drugs
  doi: 10.2165/00003495-200565160-00013
– volume: 20
  start-page: 131
  year: 2005
  ident: 666_CR15
  publication-title: Int Clin Psychopharmacol
  doi: 10.1097/00004850-200505000-00002
– volume: 45
  start-page: 167
  year: 2003
  ident: 666_CR16
  publication-title: Neuropharmacology
  doi: 10.1016/S0028-3908(03)00138-2
– volume: 7
  start-page: 317
  year: 2002
  ident: 666_CR23
  publication-title: Mol Psychiatry
  doi: 10.1038/sj.mp.4001009
– volume: 32
  start-page: 123
  issue: 2
  year: 2005
  ident: 666_CR9
  publication-title: Nucl Med Biol
  doi: 10.1016/j.nucmedbio.2004.10.001
– volume: 27
  start-page: 249
  year: 2000
  ident: 666_CR19
  publication-title: Nucl Med Biol
  doi: 10.1016/S0969-8051(00)00084-6
– volume: 25
  start-page: 1200
  year: 2003
  ident: 666_CR5
  publication-title: Clin Ther
  doi: 10.1016/S0149-2918(03)80076-0
– volume: 174
  start-page: 163
  issue: 174
  year: 2004
  ident: 666_CR25
  publication-title: Psychopharmacology
– volume: 6
  start-page: 287
  year: 1995
  ident: 666_CR3
  publication-title: Rev Contemp Pharmacother
– volume: 158
  start-page: 1843
  year: 2001
  ident: 666_CR13
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.158.11.1843
– volume: 21
  start-page: 263
  year: 1999
  ident: 666_CR24
  publication-title: Ther Drug Monit
  doi: 10.1097/00007691-199906000-00001
– volume: 21
  start-page: 1659
  issue: 10
  year: 2005
  ident: 666_CR4
  publication-title: Curr Med Res Opin
  doi: 10.1185/030079905X65484
– volume: 334
  start-page: 1
  year: 1987
  ident: 666_CR12
  publication-title: Acta Psychiatr Scand Suppl
  doi: 10.1111/j.1600-0447.1987.tb10566.x
– volume: 26
  start-page: 188
  year: 2006
  ident: 666_CR22
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/01.jcp.0000203201.34323.d3
– volume: 8
  start-page: 15
  year: 2004
  ident: 666_CR7
  publication-title: Int J Psychiatry Clin Pract
  doi: 10.1080/13651500410005504
– volume: 161
  start-page: 826
  year: 2004
  ident: 666_CR14
  publication-title: Am J Psychiatry
  doi: 10.1176/appi.ajp.161.5.826
– volume: 8
  start-page: 410
  year: 1997
  ident: 666_CR18
  publication-title: CNS Drugs
  doi: 10.2165/00023210-199708050-00009
– volume: 113
  start-page: 659
  year: 2006
  ident: 666_CR6
  publication-title: J Neural Transm
  doi: 10.1007/s00702-005-0429-7
– volume: 45
  start-page: 1400
  year: 2005
  ident: 666_CR21
  publication-title: J Clin Pharmacol
  doi: 10.1177/0091270005280860
– volume: 486
  start-page: 261
  year: 1989
  ident: 666_CR1
  publication-title: Brain Res
  doi: 10.1016/0006-8993(89)90511-8
– volume: 3
  start-page: 5
  year: 2002
  ident: 666_CR2
  publication-title: World J Biol Psychiatry
  doi: 10.3109/15622970209150599
– ident: 666_CR20
– volume: 41
  start-page: 340
  year: 2001
  ident: 666_CR11
  publication-title: J Clin Pharmacol
  doi: 10.1177/00912700122010041
– reference: 16955282 - Psychopharmacology (Berl). 2006 Oct;188(3):263-72
– reference: 24930684 - Int J Psychiatry Clin Pract. 2004;8 Suppl 1:15-8
– reference: 16238906 - Curr Med Res Opin. 2005 Oct;21(10):1659-68
– reference: 15121647 - Am J Psychiatry. 2004 May;161(5):826-35
– reference: 10832081 - Nucl Med Biol. 2000 Apr;27(3):249-54
– reference: 16633150 - J Clin Psychopharmacol. 2006 Apr;26(2):188-91
– reference: 11269575 - J Clin Pharmacol. 2001 Mar;41(3):340-6
– reference: 15721757 - Nucl Med Biol. 2005 Feb;32(2):123-8
– reference: 12809966 - Clin Ther. 2003 Apr;25(4):1200-10
– reference: 12842122 - Neuropharmacology. 2003 Aug;45(2):167-73
– reference: 15160261 - Psychopharmacology (Berl). 2004 Jul;174(2):163-76
– reference: 16465456 - J Neural Transm (Vienna). 2006 May;113(5):659-70
– reference: 16266205 - Drugs. 2005;65(16):2379-404
– reference: 11920159 - Mol Psychiatry. 2002;7(3):317-21
– reference: 2887090 - Acta Psychiatr Scand Suppl. 1987;334:1-100
– reference: 10365634 - Ther Drug Monit. 1999 Jun;21(3):263-6
– reference: 11691690 - Am J Psychiatry. 2001 Nov;158(11):1843-9
– reference: 2525060 - Brain Res. 1989 May 8;486(2):261-8
– reference: 15812262 - Int Clin Psychopharmacol. 2005 May;20(3):131-7
– reference: 12479086 - World J Biol Psychiatry. 2002 Jan;3(1):5-43
– reference: 16291715 - J Clin Pharmacol. 2005 Dec;45(12):1400-6
SSID ssj0000484
ssj0068394
Score 2.0862482
Snippet Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin...
Objectives: Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other...
SourceID proquest
pubmed
pascalfrancis
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 333
SubjectTerms Adult
Area Under Curve
Biological and medical sciences
Blood tests
Brain
Cerebellum
Cinanserin - analogs & derivatives
Citalopram - pharmacokinetics
Citalopram - pharmacology
Dose-Response Relationship, Drug
Drug Administration Schedule
Humans
Inhibitor drugs
Male
Medical sciences
Mesencephalon - drug effects
Mesencephalon - metabolism
Neurology
Neuropharmacology
Neurotransmitters
Pharmacology
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Radiopharmaceuticals
Serotonin Plasma Membrane Transport Proteins - drug effects
Serotonin Plasma Membrane Transport Proteins - metabolism
Serotonin Uptake Inhibitors - pharmacokinetics
Serotonin Uptake Inhibitors - pharmacology
Stereoisomerism
Time Factors
Tissue Distribution
Tomography
Tomography, Emission-Computed, Single-Photon
Title Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study
URI https://www.ncbi.nlm.nih.gov/pubmed/17235610
https://www.proquest.com/docview/218966364
https://www.proquest.com/docview/19634514
Volume 191
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB7BroRWQgjKKyyUOaA9oI1IY-dRLqhdWi1IrSroSpUQipzYPkFSmuwhv4E_zdh5qQf2FCWpc-iMZ76xx98H8I5SjNKhCtxAB5nLMx27saJ5JaZSpGHApWc1I1fr8PqGf90Fu7Y3p2zbKruYaAO1LDKzRv6BUhEhcxbyT_s_rhGNMpurrYLGfTg1zGXGqaNdNARibs5gNjchAYGGkZmZ82RB3O1wepZQ1DcaB6a2JjTv1kc56uFelPR36Ubn4v9A1Cak5WN41CJJnDWmfwL3VD6CB6t2r3wEF5uGlbq-xO1wyKq8xAvcDHzV9QjO-iBYP4W_TeMHkmcWlVmqxaqnPz9gYTmJKR6j1RbHrh0RZVEqFEdEvFhoVJRgzfLQ_iB-Y9fujlWBw-OPKHL8QZnty8_Z59kKv28WV1u0rLfP4Ga52F5du61gg5tx36_ckHtKRnEaT4T2tAz8dKqzyJehJBgUMhEIHoXKY7HHdCQzLfWECmS6soApLSfsOZzkRa5eAk610DGn8aZgo3dxkFJxyGSaal9l3HPA60yUZC2buRHV-JX0PMzWqont2yOrJrUD7_sh-4bK464fj4_sPoyIjS53NHXgvHOEpJ32ZdI7qQNv-7c0X80mjMhVcVsmJuJxQqkOvGi8Z_hy5DODZl_d-eVzOPNNyW_kkyav4aQ63Ko3hIuqdGy9fwyns-V8vqbrfLHefPsH380O4Q
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFD7UCloQ0fUWq-150D5Ig9lkJskKIksv7NpuWXALCyJxkpl5apN1kyL5Df4W_6NncmUf7FufQjKZeTlzbnPOfB_AO3IxSvuK21zzxGaJDu1QkV6JkRSxz5l0Ks7I2YU_uWRfl3y5BX_buzCmrbK1iZWhlllizsg_kiuiyNzz2ZfVL9uQRpniasugUe-KM1X-powt_zw9JvG-d93Tk8XRxG5IBeyEuW5h-8xRMgjjcCi0oyV345FOAlf6kly17wkuWOArxwsdTwcy0VIPKYmjp8c9peXQo3XvwX3yu47J9YJl0Bt-Zu581i8-BR41ArRn7q_xsK2oOhWAqWs4FUwuT9mDXW74xEcrkZN4dM2r8f_At3KAp0_gcRO54rjeak9hS6UDeDBravMDOJjXKNjlIS76S135IR7gvMfHLgew0xnd8hn8qRtNkDQhK8zRMBYd3PoaswoDmew_Vlzm2LY_osxyhWID-BczjYocujmOWq3FNbbt9Vhk2H_-hCLF7-RJpz_Gx-MZfpufHC2wQtl9Dpd3IssXsJ1mqXoFONJCh4zmmwSRxkIeUzLqyTjWrkqYY4HTiihKGvR0Q-JxFXW4z5VUo6pPkKQalRZ86KasauiQ237e25B7PyM0PODByILddiNEjZnJo04pLNjvRsk-mKKPSFV2k0fGwjKKii14We-efuXA9Uz0_PrWlffh4WQxO4_Opxdnu7BTH22bxqU3sF2sb9RbismKeK_SBISfd616_wCNikmi
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVKoqIQThZQrtHKAHVKuOvX4ECaHQJGooiSJIpUoVMmvv7gnsELtC_g38Iv4ds34qB3rryYqd3cvszDezO_t9AK8JYqTypGu6yo1NFqvADCT5FR8KHnkuE1apGTlfeOeX7NOVe7UDf5u7MLqtsomJZaAWaaz3yE8Jiigzdzx2ququiOV4-mH9y9QCUvqgtVHTqFbIhSx-U_WWvZ-NydRvbHs6WZ2dm7XAgBkz285Nj1lS-EEUDLiylHDtaKhi3xaeINj2HO5y5nvScgLLUb6IlVADKujo6biOVGLg0Lz3YNfXRVEPdj9OFssvHQwwfQO0-uFRGlLxQTv6NpsbNOerVklnamuFBV3ZUy1hFlsIeX_NMzKWqlQ2_p8Gl3A4fQgP6jwWR9XCewQ7MunD3rw-qe_D8bLixC5OcNVd8cpO8BiXHVt20Yf9NgQXj-FP1XaC5BdprjeKMW_J1zeYlozIhAZYKptj0wyJIs0k8i0aYEwVSoJ3vTm13vCf2DTbY55i9_od8gSvCVdn30bj0Ry_LidnKyw5d5_A5Z1Y8yn0kjSRzwGHiquA0XhdLtK3wI2oNHVEFClbxswywGpMFMY1l7qW9PgRtizQpVXDsmuQrBoWBrxth6wrIpHb_ny4ZfduRKBVwf2hAQfNQgjroJOFrYsYcNR-pWihj4B4ItObLNTxllGObMCzavV0M_u2o3PpF7fOfAR75Hbh59ni4gD2q31u3cX0Enr55ka-ogQtjw5rV0D4ftfe9w-B2k89
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Higher+serotonin+transporter+occupancy+after+multiple+dose+administration+of+escitalopram+compared+to+citalopram%3A+an+%5B123I%5DADAM+SPECT+study&rft.jtitle=Psychopharmacology&rft.au=Klein%2C+Nikolas&rft.au=Sacher%2C+Julia&rft.au=Geiss-Granadia%2C+Thomas&rft.au=Mossaheb%2C+Nilufar&rft.date=2007-04-01&rft.issn=0033-3158&rft.volume=191&rft.issue=2&rft.spage=333&rft_id=info:doi/10.1007%2Fs00213-006-0666-y&rft_id=info%3Apmid%2F17235610&rft.externalDocID=17235610
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0033-3158&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0033-3158&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0033-3158&client=summon